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Abstract: Preclinical studies using animal models of fragile X syndrome have yielded several agents
that rescue a wide variety of phenotypes. However, translation of these treatments to humans with
the disorder has not yet been successful, shedding light on a variety of limitations with both animal
models and human trial design. As members of the Clinical Trials Committee of the National Fragile X
Foundation, we have discussed a variety of recommendations at the level of preclinical development,
transition from preclinical to human projects, family involvement, and multi-site trial planning. Our
recommendations are made with the vision that effective new treatment will lie at the intersection of
innovation, rigorous and reproducible research, and stakeholder involvement.
Keywords: fragile X syndrome; clinical trials; treatment development; best practices
1. Introduction
Since the proposal of the “mGluR theory of fragile X syndrome (FXS)” over a decade ago, there
has been an explosion of preclinical small molecule investigation in FXS leading to a number of
mechanistically-targeted treatments moving into FXS human study. Despite significant pre-clinical
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data supporting translation of many drugs to humans, combined with some success in early-phase
studies, no definitive large-scale placebo-controlled trials have met primary endpoints leading to
drug use indications specific to FXS. As leaders and stakeholders in the field of FXS, we recognize
the importance of issuing recommendations for methodology, including study design and strategies,
which can maximize potential for success for the bench to bedside treatment development pathway.
With this in mind, we review key aspects of the process of FXS treatment development with an eye
towards ensuring that successful trials of new treatments, incorporating innovative research and
stakeholder concerns, can be enacted.
2. Fragile X Clinical and Research Consortium Clinical Trials Committee
The National Fragile X Foundation (NFXF) has developed a Clinical Trials Committee (CTC)
structure made up of Fragile X Clinical and Research Consortium (FXCRC) members, FXS clinicians,
expert FXS trialists, outcome measure experts in the field, and family stakeholders to assist and
support treatment developments. This committee reports and provides recommendations to the
NFXF’s Facilitation of Research Oversight Group (FROG). The authors of this commentary all sit on the
CTC. The CTC is designed to provide a one-stop point of contact to interface with industry, academic,
and other partners seeking to move forward FXS-focused new treatment development at any stage.
The CTC centralizes new treatment development support and advising in an orphan disease condition
of great interest to potential business and academic partners. Moving forward the FXCRC Clinics have
embraced the concept that, with many potential trials in FXS proposed, it will be critical to protect
patients and optimize FXS participant resources through careful discussions about proposed trials
and development programs with the CTC. The CTC will review preclinical data in early stages of
drug development and subsequently help with recommendations regarding trial designs, outcome
measures, and development strategy for agents showing promise on appropriate rigor preclinical
and/or early phase clinical studies.
Given the history of large-scale trial failures, and the large list of mechanistic targets and treatment
development partners, it is critical for the FXS field to create a collaborative framework of expertise.
The latter include those experts who led the first round of trials and representatives of affected families,
who will collaborate in the design of trials and drug development paths that can capitalize on lessons
learned and result in clear delineation of the drugs that have a positive impact in FXS and, ultimately,
in the successful registration of these drugs for use by patients. Given this, it is advised that sponsors
of all drug development in FXS that have reached the stage of multi-site Phase II or III trials, hold
advisory meetings with and seek endorsement from the CTC, prior to use of FXCRC Clinics to carry
out further development in FXS. Those seeking to engage the CTC may contact the National Fragile X
Foundation CTC liaison (J.D.W.; jayne@fragilex.org) to initiate a dialogue. This recommendation is
made to ensure that study sponsors receive accurate information facilitating the conduct of trials in
FXS including broad stakeholder input.
3. Preclinical Development
Experience with mouse models of FXS and other neurodevelopmental disorders has demonstrated
their value as experimental systems for proof-of-principle assessments of new interventions [1].
Nonetheless, this work has also shown that phenotypes that are improved in mice do not necessarily
translate directly to affected individuals [2]. Therefore, our field needs to emphasize the development
of preclinical animal testing that can be evaluated in a similar manner in humans [3]. As important as
the limited relevance of animal models to the human disorder, is the concern about reproducibility of
animal data. The NIH has published guidelines promoting standardization of experimental paradigms
and “best preclinical practices” for animal model work [4] and these have begun to be applied to
neurodevelopmental disorders [5]. We recommend that any new treatment should be evaluated
in blinded randomized experiments performed for multiple phenotypes in different domains (e.g.,
electrophysiological, molecular, behavioral), with some phenotypes being directly translatable to
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humans, and reversal of phenotypes shown in at least two independent laboratories [2] and ideally in
several species, given the fact that rat and Drosophila models of FXS also exist.
The presentation and publication of negative preclinical testing results is crucial to inform study
design, outcome measure selection, and execution of first in human studies. Thus, this practice
should be encouraged and is of importance to our field. The FXS field is challenged early on in drug
development in part by a publication culture focused on “positive” preclinical data. Understanding
which particular treatments may not improve murine or other animal phenotypes may be as important
as understanding the aspects of success with a specific drug.
In the same manner that human trials may not result in efficacious treatments for every individual
with FXS, understanding variation within animal treatment response in vivo may provide early clues
to features that may predict treatment response later in affected patients. Preclinical focus to date
on murine findings has been on rescue or non-rescue with drug versus placebo treatment across
various behavioral, molecular, and neuroanatomical assays and not on variation within treatment
response. Further investigation into potential variability in preclinical treatment response may aide
future planning when treatments move into human studies.
Considering that mouse or other animal models work only provides evidence of treatment
adequacy but not of specific outcomes, the possibility of skipping altogether in vivo model testing
has been raised. Instead, in vitro evaluation of iPSC-derived neural cells offers the opportunity of
testing directly cells from individuals with FXS and showing correction of cellular abnormalities, data
that not only could be used for demonstrating treatment effectiveness but also subject selection [6].
However, this intriguing new approach does not test extension of cellular changes to neurobehavioral
outcomes and will need to be systematically compared with current animal model standards prior to
its full implementation [2]. In summary, the rigor, reproducibility, and specific findings of treatment
development preclinical data should be evaluated in detail in planning for the scope and potentially
specific aspects of the design of first in FXS human studies.
4. Transition from Preclinical Studies to Human Subject Projects
Once preclinical work has demonstrated the scientific validity of a particular treatment through
in vivo and/or in vitro studies, other elements of the experimental data can inform the subsequent
steps. For initial human FXS trials, a project relying on single laboratory murine data or an
iPSC model alone may be best served moving first into a human Phase Ib proof-of-concept target
engagement study versus a brisk move into a large-scale first in FXS Phase II study. The latter would
be more adequate for treatments supported by multiple preclinical studies providing convergent
evidence and/or supported by small initial target engagement focused Phase Ib work in FXS. Drugs
for which there is improvement of a directly translatable animal pharmacodynamic marker (e.g.,
event-related potential (ERP) abnormality) can be quickly tested initially in early phase human
pharmacokinetic/pharmacodynamic (PK/PD) studies applying the biomarker prior to moving to
larger clinical trials to help inform a large-scale study. Elements of adaptive trial design can be
considered even in the earliest stages of human projects in FXS to facilitate the establishment of a
predictive model incorporating biological markers and clinical outcomes.
A process of de-risking large-scale multi-site projects in our field, utilizing well-conceived proof of
concept early human studies, is quite possible. Such early work would need to include use of extensive
objective and/or directly observable measures of brain function, communication, and behavior in
order to determine potential clinically-relevant changes with treatment. Use of a crossover design,
while potentially problematic in large-scale studies, given increased length, treatment expectation,
and potential carryover effects on proxy outcome measures, may provide additional strength to Phase
Ib projects that focus primarily on objective evaluations of target engagement. A rigorously designed
Phase Ib trial in FXS may allow for an earlier go- or no-go decision on future larger scale multi-site
studies of a drug, by requiring significantly less investment -in dollars and stakeholder commitment-
than approaches with initial large-scale Phase II projects and by allowing for more informed biomarker
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and outcome measure selection based on a particular treatment or a particular cohort of individuals
with FXS.
Drugs targeting brain mechanisms in FXS with predominant effects on molecular, anatomical,
and electrophysiological parameters, resulting in reversal of multiple and diverse phenotypes in
animal models, would best move into human therapy through a Phase Ib PK/PD study looking at a
broad range of objective outcomes, as optimal outcome measures are too difficult to predict in humans
in this kind of scenario. Drugs that have an expected or known behavioral effect deemed important in
FXS that has been replicated in multiple labs, and which target behavior as supportive care, may move
faster to Phase II or Phase III trials with outcome measures directed at the predicted behavioral targets.
Whether human studies entered in a gradual manner or with a rapid move into regulatory grade
Phase II and III projects, the transition into and through the human stages of treatment development
in FXS will benefit from many practice recommendations put forth below. Although early phase trials
focused on safety or PK/PD could be conducted at a single site, studies evaluating efficacy benefit
from a multi-site design. Regardless of size and scope, in the case of rare diseases like FXS, expertise in
the disorder at the trial sites enhances the possibility of successful implementation and stakeholder
satisfaction as discussed in more detail below.
5. Best Practices in Human Subjects Projects: Detecting Treatment Response
Heterogeneity in the clinical presentation of FXS relates to several factors including FMR1 gene
variations and background genetic and epigenetic effects, environmental stimulation, as well as
negative life experiences. These factors lead to variability not only in the symptoms of FXS that
individuals manifest but also in their response to treatment [2,7]. Likely, not all individuals with FXS
will have a uniformly positive clinical response even to the best targeted treatments for FXS. Placebo
effects are also remarkable in our field, especially when parent questionnaires regarding interfering
behavior are used. Animal models have helped to guide us to specific treatments for patients, such
as mGluR5 antagonists, the GABA-B receptor agonist arbaclofen, minocycline, metformin and other
agents. However, trials with these agents have been potentially complicated by the presence of
subgroups of responders, making entire cohort efficacy difficult to demonstrate. In this context,
utilization of biomarkers such as EEG findings or responses in iPSC-derived neuronal cell cultures
may be able to identify potential treatment responses for specific individuals with FXS, helping with
stratification or selection of subjects for future trials.
The large placebo effect and selection of outcomes have been challenges in clinical trials in FXS.
For example, in a well powered study reported by Berry-Kravis and colleagues (2016) there was a
remarkable change in caregiver measures in the placebo group [8]. This significant placebo effect could
have obscured true treatment-related changes in the active drug group. In the related field of autism
spectrum disorder (ASD), a meta-analysis of 25 studies involving 1315 subjects, investigating placebo
response in medication trials, demonstrated a “moderate effect size” for overall placebo response
(Hedges’ g = 0.45, 95% confidence interval (0.34–0.56); P < 0.001) [9]. Reports like this raise the question
whether we ought to expect a greater placebo effect when employing caregiver measures of abnormal
behavior, in patients with neurodevelopmental disorders than in other populations [10]. If the answer
is an affirmative one, that may reflect particularly high expectations among caregivers of individuals
with developmental disabilities, including FXS, for treatments targeting key symptoms and reduction
of disease burden [10], especially when widespread success of preclinical models is highly publicized.
The strength of the placebo response in clinical trials for FXS supports the need to use more objective
neurobehavioral and functional measures and/or to develop approaches that substantially mitigate
biased reporting of treatment effects. Like all effective outcome measures, such “placebo-resistant”
evaluations would need to be psychometrically sound (e.g., with known test-retest reliability), sensitive
to change, and reflect improvements that are meaningful in the daily life of individuals with FXS.
Ideally, the relationships between these measures and the underlying neural systems impaired in FXS
should be understood so that in any given trial a measure can be chosen because it is proximal to the
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mechanism of action of the drug under study. It would also be useful if the clinical outcome measures
have relevance to the neural cellular and circuit targets evaluated in preclinical studies [2].
Unfortunately, available outcome measures, including those in use in ongoing trials, generally do
not meet all of the criteria outlined above [11]. Nonetheless, progress is being made in establishing the
psychometric adequacy of several objective measures for quantifying change in important domains of
general cognitive functioning [12], as well as specific areas of language [13] and executive function [14].
Preliminary results suggest that many of these promising measures are feasible for individuals of
a wide range of ages and abilities, display minimal practice effects and strong test-retest reliability,
and have good construct validity. At the same time, it is important to acknowledge that performance
on these novel measures, as for most cognitive and behavioral measures, is likely to be affected by a
number of skills and motivational factors and, thus, will reflect the functioning and complex interaction
of multiple neural circuits that may result in attenuation of their sensitivity to detect drug efficacy.
Also, we should acknowledge that placebo effects may occur even when using objective performance
measures in individuals with intellectual disability [15].
Quantitative measures of pathophysiology are generally considered as potential continuous
measures of efficacy; however, they can be equally considered as baseline predictors of treatment
response. Genetic and blood-based molecular markers have already shown promise as identifiers
of potential responders in drug trials in FXS [16]. While there is a high bar for official biological
marker qualification as FDA-accepted surrogate biomarkers that can be used as regulatory endpoints
in trials, use of biomarkers to identify target engagement, generally, and subgroups of potential
responders with FXS is tractable in the near term. An approach like this may be able to parse the
sometimes underappreciated heterogeneity of FXS in early trials, in order to guide subject selection
or stratification in large-scale treatment trials. An example of this approach is ongoing work using
single-dose placebo-controlled probe studies in adolescents and adults with FXS [17]. Another strategy,
which should be incorporated as a standard procedure for all large-scale trials, is to collect blood
samples for evaluation of genetic and other molecular markers. Development of brain- or blood-based
markers will enrich research populations with responders to enhance treatment success and de-risk
the perils faced by trials similar to unsuccessful past trials in FXS, which had broad inclusion criteria
and relied on placebo-sensitive measures. For this reason, the NFXF has developed a NFXF Biobank™
program to receive biological samples and associated clinical data from persons with FXS including
trial participants to provide a repository that will benefit biomarker understanding for the field
regardless of final trial result.
Previous publications have examined the current status of outcome measures in FXS, providing
practical recommendations and future directions [11,18]. Attributes considered critical for novel
and improved outcome measures are the following: quantitative; reflecting brain circuits, function,
or molecular pathways affected in FXS; relevant to experimental models of FXS; and reflecting quality of
life of individuals with FXS. An example of these promising measures is event related potentials (ERPs),
using repetitive auditory or visual stimuli and measuring habituation to the stimuli which is known to
be abnormal because of inhibitory (GABA) deficits in FXS. Significant improvements in this measure
were documented by Schneider and colleagues [19] in a controlled trial of minocycline compared to
placebo and similar ERPs are being studied in the NeuroNext trial (FX-LEARN) with AFQ056 and
parent-implemented language intervention (PILI, NCT02920892). Another type of promising measures
are molecular markers reflecting core abnormalities in FXS, such as excessive protein production in
FXS. For instance, levels of the matrix metalloproteinase 9 (MMP9) that are up-regulated in FXS have
been shown to be reduced by administration of minocycline [20].
Biomarkers sensitive to change and correlated or predictive of clinical behavioral changes are
of particular interest. Thus, assessment of how quantitative measures such as auditory ERPs, eye
tracking and molecular biomarkers correlate with the clinical outcomes measured by behavioral
ratings, cognitive and language tests, is critical. A number of recent phase 1b and 2a trials in FXS have
incorporated all of these measures (NeuroNext AFQ056 (NCT02920892), metformin (NCT03479476),
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AZD7325 (NCT03140813), BPN14770 (NCT03569631)), such that the outcomes of these studies
will improve our understanding of the relationships between biomarkers and clinical behavioral
measures. An NIH multisite initiative called the Autism Biomarkers Consortium for Clinical Trials
(www.asdbiomarkers.org) aims to identify a useful set of such tools.
Lessons learned from prior unsuccessful clinical trials in FXS suggest that greater emphasis on
clinician- than caregiver-based measures; training systems for caregivers, clinicians, and other raters
(e.g., teachers); evaluations in multiple settings (e.g., school, home, workplace); and behavioral ratings
in real time on an electronic device or by videotaping, are approaches that could complement or replace
current instruments, in particular behavioral rating scales. Finally, careful attention to other study
aspects such as randomization and placebo inclusion in most early- and all late-phase trials; longer
trial duration (to capture cognitive and adaptive changes); approaches to minimize placebo effects
(e.g., placebo run-ins, enrichment in non-placebo responders, rater training); and younger cohort age
would maximize the possibility of success.
6. Family Involvement
It is important that a family stakeholder voice is heard in FXS treatment development programs.
Stakeholders can optimize recruitment and retention for FXS clinical trials. To accomplish this,
it is important to provide parents with the most detailed possible information about all aspects
of the trial. This would include: inclusion/exclusion criteria, length of the study, location,
number/length/flexibility of visits, details on what will occur at each visit, and whether there is any
travel/participation reimbursement available. It is imperative that family stakeholders understand the
clinical manifestation targeted by the drug or intervention under study. It should also be noted that
inclusion of an open-label extension phase following a placebo-controlled treatment will inherently
boost study recruitment and retention. Enhanced communication with families about trial details, such
as inclusion criteria and endpoints, should include the importance of adhering to the study design and
avoiding attempts to “boost” reporting of a certain feature or behavior to facilitate study participation.
Education on the implications of inaccurate reporting or embellishment of symptoms on the likelihood
of obtaining appropriate results, which may benefit all stakeholders, is another key issue that should
be communicated to families.
Clinicians working with FXS family stakeholders often note the high level of motivation and
commitment regarding treatments or clinical trials that may benefit their loved one with FXS. Given
this zeal, parents/caregivers may be inadvertently drawn to a new treatment that may not be suitable
for their family member with FXS. There are many reasons why a trial could not be an appropriate fit
for a specific individual with FXS, including safety and efficacy concerns, inclusion or exclusion criteria,
outcome measures, length of project and/or number of appointments required. From a caregiver
viewpoint, it is important that drug trials have a protocol that includes an operations manual detailing
the accommodations to take place, such as staff training regarding FXS, visual supports and extra time
during appointments. A well-designed project that is “FXS-friendly” will ensure that families are met
with the expertise and commitment necessary to maximize the opportunity for positive outcomes.
It may be useful to ask family raters (caregivers) what they have heard about the
treatment/medication, to yield information about any bias that may be likely in their future
assessments. Raters should be given explicit permission to not report improvement if none occurred,
to emphasize observed behavior rather than make guesses or inferences or rely overly on third parties,
and to remain agnostic to the extent possible about the probability of treatment benefit.
As a patient advocacy organization that has been serving the FXS community of families and
professionals for nearly 35 years, the National Fragile X Foundation strongly recommends that
parents have a well-defined and meaningful role in providing input regarding clinical trials and
new treatment development. There has been a history of unsuccessful trials, parental confusion
regarding clinical endpoints, disappointment and, at times, anger over the lack of opportunity for
and/or discontinuation of open label extensions among other concerns. Some of these pitfalls can be
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avoided or, at least, minimized by ensuring that researchers fully understand the worries, concerns,
wants, needs, and hopes of parents and other family members. Such input can for example include,
among others, recommendations about targets of treatment of importance to families in terms of quality
of life, preferred routes of drug administration, advice on the conduct of research procedures within
a visit day, feasibility of study designs, and strategies of communication of trials to the community.
By providing such an opportunity for family input during protocol development, researchers and,
ultimately, those in pharmaceutical industry leadership and decision-making positions, will have
access to information that will greatly increase the likelihood of successful trial outcomes and, most
importantly, lead to better lives for those with FXS. Development of a family advisory committee as a
resource to treatment development programs should meet these needs.
Understanding the impact of social media on FXS treatment development is also of importance to
our field. Because it is not possible to completely monitor Facebook and other types of social media,
trial sponsors or investigators should include a stand-alone document on the use of social media
and ask parents to sign it in order to participate in the trial. It should state that it is acceptable for
participants to post about their experience with the study (e.g., how accommodating the staff is, how
to navigate the hospital, tricks they have found successful in helping their family member with FXS
participate, and that they are glad to be supporting research). However, the document should also
clearly describe what comments are inappropriate because they may bias study reporting such as those
about side effects, how the patient is doing, whether they think they are on drug or placebo or how
they think other families should rate scales or questionnaires to qualify for the study.
Many clinical trials have extensively evaluated children and adults with FXS. Assessments might
include IQ or equivalent tests, adaptive behavior, language, and testing regarding autism spectrum
disorder. Much of this information could be beneficial for families to have for school programming and
for additional support services. This testing can be expensive and not readily available to all families.
The CTC recommends that relevant findings be shared with parents and guardians and provided to
them in a written format that would be readily understood by providers or professionals supporting
the child or adult with FXS.
7. Multi-Site Trial Planning
Once FXS treatment development has moved to the stage of large-scale Phase II or Phase III
investigations, opportunities exist to enhance project executions, fidelity of data gathering, and to
facilitate broad human subjects’ recruitment and retention. It is important that within large-scale
projects an operations manual that details accommodations to individuals and families with FXS, as the
one described in the preceding section, is developed. A well-designed project that is “FXS-friendly” will
ensure that families are met with the expertise and commitment necessary to maximize the opportunity
for positive outcomes. Rater and investigator training including presentations by FXS thought leaders
and family stakeholders will ensure FXS specificity, which will overcome barriers inherent in “off
the shelf” central nervous system (CNS) trial approaches grafted into a unique neurodevelopmental
disorder setting.
Such multi-site work should build upon existing FXS centers and clinics with content expertise.
Luckily, over a decade of multi-site trial projects in our field has laid a foundation for large-scale
trials that has united clinical centers with content expertise with best trial practices and the standard
operating procedures of good clinical research. While initial site qualification efforts and trainings
should involve FXS content expertise, ongoing support of fidelity of study execution across sites is
essential. There are also great opportunities for centralized future potential support of recruitment and
retention efforts in large-scale projects given the infrastructure within the FXCRC supported by the
National Fragile X Foundation.
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8. Summary of Key Recommendations
Much has been learned in the burgeoning FXS treatment development field in the past decade.
We have set forth to make many recommendations to enhance the success and stakeholder benefits
from future treatment development in our field. From focusing on reproducible early preclinical data
to moving towards quantitative markers of pathophysiology as markers of target engagement and
change with treatment, clear directions have been defined to broadly support success navigating the
chasm between treatment ideas and success in placebo-controlled trials. Along the way we emphasize
the importance of engaging the FXS stakeholder community to ensure the meaningfulness of project
results and the appropriateness of project procedures from a family and affected individual perspective.
Our group remains optimistic at the near-term prospect for impactful treatment development in FXS.
We believe that our advocacy and engagement with these processes will work to maximize success
and we embrace the opportunity to support the best practices we have defined in this commentary in
partnership with treatment developers worldwide.
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